Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90. doi:10.3322/caac.20107.
Article
PubMed
Google Scholar
Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25–34. doi:10.1016/s1470-2045(08)70285-7.
Article
CAS
PubMed
Google Scholar
Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, SHARP Investigators Study Group, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–90. doi:10.1056/NEJMoa0708857.
Article
CAS
PubMed
Google Scholar
Dancey J, Zee B, Osoba D, Whitehead M, Lu F, Kaizer L, et al. Quality of life scores: an independent prognostic variable in a general population of cancer patients receiving chemotherapy. The National Cancer Institute of Canada Clinical Trials Group. Qual Life Res. 1997;6:151–8.
Article
CAS
PubMed
Google Scholar
Braun DP, Gupta D, Staren ED. Quality of life assessment as a predictor of survival in non-small cell lung cancer. BMC Cancer. 2011;11:353. doi:10.1186/1471-2407-11-353.
Article
PubMed
PubMed Central
Google Scholar
Braun DP, Gupta D, Grutsch JF, Staren ED. Can changes in health related quality of life scores predict survival in stages III and IV colorectal cancer? Health Qual Life Outcomes. 2011;9:62. doi:10.1186/1477-7525-9-62.
Article
PubMed
PubMed Central
Google Scholar
Steel JL, Geller DA, Robinson TL, Savkova AY, Brower DS, Marsh JW, et al. Health-related quality of life as a prognostic factor in patients with advanced cancer. Cancer. 2014;120:3717–21. doi:10.1002/cncr.28902.
Article
PubMed
PubMed Central
Google Scholar
Grunwald V, Soltau J, Ivanyi P, Rentschler J, Reuter C, Drevs J. Molecular targeted therapies for solid tumors: management of side effects. Onkologie. 2009;32:129–38. doi:10.1159/000194949.
PubMed
Google Scholar
Miyake H, Kurahashi T, Yamanaka K, Kondo Y, Takenaka A, Inoue TA, et al. Impact of sorafenib on health-related quality of life in Japanese patients with metastatic renal cell carcinoma: a prospective evaluation. BJU Int. 2010;106:1643–7. doi:10.1111/j.1464-410X.2010.09437.x.
Article
PubMed
Google Scholar
Trask PC, Bushmakin AG, Cappelleri JC, Bycott P, Liau K, Kim S. Health-related quality of life during treatment for renal cell carcinoma: results from a phase II study of axitinib. Acta Oncol. 2008;47:843–51. doi:10.1080/02841860802047395.
Article
CAS
PubMed
Google Scholar
Schadendorf D, Amonkar MM, Stroyakovskiy D, Levchenko E, Gogas H, de Braud F, et al. Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma. Eur J Cancer. 2015;51:833–40. doi:10.1016/j.ejca.2015.03.004.
Article
CAS
PubMed
Google Scholar
Nardone B, Hensley JR, Kulik L, West DP, Mulcahy M, Rademaker A, et al. The effect of hand-foot skin reaction associated with the multikinase inhibitors sorafenib and sunitinib on health-related quality of life. J Drugs Dermatol. 2012;11:e61–5.
PubMed
Google Scholar
Brunocilla PR, Brunello F, Carucci P, Gaia S, Rolle E, Cantamessa A, et al. Sorafenib in hepatocellular carcinoma: prospective study on adverse events, quality of life, and related feasibility under daily conditions. Med Oncol. 2013;30:345. doi:10.1007/s12032-012-0345-2.
Article
PubMed
Google Scholar
Boursier J, Cesbron E, Tropet AL, Pilette C. Comparison and improvement of MELD and Child-Pugh score accuracies for the prediction of 6-month mortality in cirrhotic patients. J Clin Gastroenterol. 2009;43:580–5. doi:10.1097/MCG.0b013e3181889468.
Article
PubMed
Google Scholar
Minagawa M, Ikai I, Matsuyama Y, Yamaoka Y, Makuuchi M. Staging of hepatocellular carcinoma: assessment of the Japanese TNM and AJCC/UICC TNM systems in a cohort of 13,772 patients in Japan. Ann Surg. 2007;245:909–22. doi:10.1097/01.sla.0000254368.65878.da.
Article
PubMed
PubMed Central
Google Scholar
Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649–55.
Article
CAS
PubMed
Google Scholar
Fukuhara S, Bito S, Green J, Hsiao A, Kurokawa K. Translation, adaptation, and validation of the SF-36 health survey for use in Japan. J Clin Epidemiol. 1998;51:1037–44.
Article
CAS
PubMed
Google Scholar
Fukuhara S, Ware Jr JE, Kosinski M, Wada S, Gandek B. Psychometric and clinical tests of validity of the Japanese SF-36 health survey. J Clin Epidemiol. 1998;51:1045–53.
Article
CAS
PubMed
Google Scholar
Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30:52–60. doi:10.1055/s-0030-1247132.
Article
CAS
PubMed
Google Scholar
Japan Clinical Oncology Group. Common Terminology Criteria for Adverse Events (CTCAE) v4.0-Japan Clinical Oncology Group. 2009. Available at http://www.jcog.jp/doctor/tool/CTCAEv4J_20160310.pdf. Accessed 25 Mar 2016.
Bukowski R, Cella D, Gondek K, Escudier B. Effects of sorafenib on symptoms and quality of life: results from a large randomized placebo-controlled study in renal cancer. Am J Clin Oncol. 2007;30:220–7. doi:10.1097/01.coc.0000258732.80710.05.
Article
CAS
PubMed
Google Scholar
Koldenhof JJ, Witteveen PO, de Vos R, Walraven M, Tillier CN, Verheul HM, et al. Symptoms from treatment with sunitinib or sorafenib: a multicenter explorative cohort study to explore the influence of patient-reported outcomes on therapy decisions. Support Care Cancer. 2014;22:2371–80. doi:10.1007/s00520-014-2223-2.
CAS
PubMed
Google Scholar
Shomura M, Kagawa T, Shiraishi K, Hirose S, Arase Y, Koizumi J, et al. Skin toxicity predicts efficacy to sorafenib in patients with advanced hepatocellular carcinoma. World J Hepatol. 2014;6:670–6. doi:10.4254/wjh.v6.i9.670.
Article
PubMed
PubMed Central
Google Scholar
Estfan B, Byrne M, Kim R. Sorafenib in advanced hepatocellular carcinoma: hypertension as a potential surrogate marker for efficacy. Am J Clin Oncol. 2007;36:319–24. doi:10.1097/COC.0b013e3182468039.
Article
Google Scholar
Koschny R, Gotthardt D, Koehler C, Jaeger D, Stremmel W, Ganten TM. Diarrhea is a positive outcome predictor for sorafenib treatment of advanced hepatocellular carcinoma. Oncology. 2013;84:6–13. doi:10.1159/000342425.
Article
CAS
PubMed
Google Scholar
Yeo W, Mo FK, Koh J, Chan AT, Leung T, Hui P, et al. Quality of life is predictive of survival in patients with unresectable hepatocellular carcinoma. Ann Oncol. 2006;17:1083–9. doi:10.1093/annonc/mdl065.
Article
CAS
PubMed
Google Scholar
Diouf M, Filleron T, Barbare JC, Fin L, Picard C, Bouché O, et al. The added value of quality of life (QoL) for prognosis of overall survival in patients with palliative hepatocellular carcinoma. J Hepatol. 2013;58:509–21. doi:10.1016/j.jhep.2012.11.019.
Article
PubMed
Google Scholar
Behrens G, Matthews CE, Moore SC, Freedman ND, McGlynn KA, Everhart JE, et al. The association between frequency of vigorous physical activity and hepatobiliary cancers in the NIH-AARP Diet and Health Study. Eur J Epidemiol. 2013;28:55–66. doi:10.1007/s10654-013-9767-1.
Article
PubMed
PubMed Central
Google Scholar
Ukawa S, Tamakoshi A, Wakai K, Kurozawa Y. Associations of daily walking and television viewing time with liver cancer mortality: findings from the Japan Collaborative Cohort Study. Cancer Causes Control. 2014;25:787–93. doi:10.1007/s10552-014-0380-8.
Article
PubMed
Google Scholar
Cron DC, Friedman JF, Winder GS, Thelen AE, Derck JE, Fakhoury JW, et al. Depression and frailty in patients with end-stage liver disease referred for transplant evaluation. Am J Transplant. 2016;16:1805–11. doi:10.1111/ajt.13639.
Article
CAS
PubMed
Google Scholar
Lai JC, Feng S, Terrault NA, Lizaola B, Hayssen H, Covinsky K. Frailty predicts waitlist mortality in liver transplant candidates. Am J Transplant. 2014;14:1870–9. doi:10.1111/ajt.12762.
Article
CAS
PubMed
PubMed Central
Google Scholar
Chang SF, Lin PL. Frail phenotype and mortality prediction: a systematic review and meta-analysis of prospective cohort studies. Int J Nurs Stud. 2015;52:1362–74. doi:10.1016/j.ijnurstu.2015.04.005.
Article
PubMed
Google Scholar
Gill TM, Gahbauer EA, Han L, Allore HG. Trajectories of disability in the last year of life. N Engl J Med. 2010;362:1173–80. doi:10.1056/NEJMoa0909087.
Article
CAS
PubMed
PubMed Central
Google Scholar
Sinn DH, Cho JY, Gwak GY, Paik YH, Choi MS, Lee JH, et al. Different survival of Barcelona clinic liver cancer stage C hepatocellular carcinoma patients by the extent of portal vein invasion and the type of extrahepatic spread. PLoS One. 2015;10, e0124434. doi:10.1371/journal.pone.0124434.
Article
PubMed
PubMed Central
Google Scholar
Miyahara K, Nouso K, Morimoto Y, Tomoda T, Kobayashi S, Takeuchi Y, et al. Evaluation of the effect of sorafenib using serum NX-des-γ-carboxyprothrombin in patients with hepatocellular carcinoma. Hepatol Res. 2013;43:1064–70.
CAS
PubMed
Google Scholar
Farinati F, Vitale A, Spolverato G, Pawlik TM, Huo TL, Lee YH, et al. Development and validation of a new prognostic system for patients with hepatocellular carcinoma. PLoS Med. 2016;13, e1002006. doi:10.1371/journal.pmed.1002006.
Article
PubMed
PubMed Central
Google Scholar
Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;31(379):1245–55. doi:10.1016/S0140-6736(11)61347-0.
Article
Google Scholar
Montella L, Addeo R, Cennamo G, Vincenzi B, Palmieri R, Sperlongano P, et al. Sorafenib in elderly patients with advanced hepatocellular carcinoma: a case series. Oncology. 2013;84:265–72. doi:10.1159/000345558.
Article
CAS
PubMed
Google Scholar